论文部分内容阅读
目的探讨PDE4B、BCL-2在不同类型B细胞非霍奇金淋巴瘤(B cell non-Hodgkin Lymphoma,B-NHL)中的表达及其意义。方法采用免疫组化方法检测93例不同类型B-NHL和10例反应性增生淋巴结中PDE4B、BCL-2的表达,并进行对比分析。结果 PDE4B、BCL-2在不同类型B-NHL中均有不同程度的表达,PDE4B在淋巴浆细胞淋巴瘤(LPL)、滤泡性淋巴瘤(FL)、边缘区淋巴瘤(MZL)表达较高;伯基特淋巴瘤(BL)均为阴性表达,各组间比较无统计学意义(P>0.05)。BCL-2在FL与弥漫性大B细胞淋巴瘤(DLBCL)、淋巴母细胞性淋巴瘤(LBL)、黏膜相关淋巴组织结外边缘区淋巴瘤(MALT)各组表达比较有统计学意义(P<0.05)。PDE4B在DLBCL的GCB亚型、non-GCB亚型阳性表达分别为61.54%(16/26)3,1.43%(11/35),差异有统计学意义(P<0.05)。结论 PDE4B、BCL-2在不同类型B-NHL中均有不同程度的表达,二者在B-NHL的发生、发展中可能起着一定的作用。PDE4B表达与B-NHL的恶性程度和侵袭性可能存在负相关;BCL-2是诊断FL的一个重要指标。
Objective To investigate the expression and significance of PDE4B and BCL-2 in different types of B cell non-Hodgkin Lymphoma (B-NHL). Methods The expressions of PDE4B and BCL-2 in 93 cases of different types of B-NHL and 10 cases of reactive hyperplasia lymph nodes were detected by immunohistochemistry and compared. Results PDE4B and BCL-2 were expressed in different degrees in different types of B-NHL. PDE4B was highly expressed in lymphoplasmacytic lymphoma (LPL), follicular lymphoma (FL) and marginal zone lymphoma (MZL) ; Burkitt’s lymphoma (BL) were negative expression, no significant difference between the groups (P> 0.05). The expression of BCL-2 in FL was significantly different from those in DLBCL, LBL and MALT (P <0.05). The positive expression rates of GCB subtype and non-GCB subtype of PDE4B in DLBCL were 61.54% (16/26) 3 and 1.43% (11/35), respectively, with significant difference (P <0.05). Conclusions Both PDE4B and BCL-2 express differently in different types of B-NHL, both of which may play a role in the occurrence and development of B-NHL. There may be a negative correlation between the expression of PDE4B and the malignancy and invasiveness of B-NHL. BCL-2 is an important indicator in the diagnosis of FL.